WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16

Similar documents
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

HPV infections and potential outcomes

Management that provides continuity of care for women

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Cervical Conization. 1

Understanding Your Pap Test Results

Twenty-first refresher course. Chan Kit Sheung

CPC on Cervical Pathology

HPV-related papillomatous-condylomatous lesions in female anogenital area

Vaginal intraepithelial neoplasia

VIN/VAIN O C T O B E R 3 RD J M O R G A N

What Causes Cervical Cancer? Symptoms of Cervical Cancer

Colposcopy. Attila L Major, MD, PhD

Managament of Abnormal Cervical Cytology and Histology

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Becoming a colposcopist: Colposcope case studies

PREINVASIVE DISEASE OF THE LOWER GENITAL TRACT DR AI LING TAN GYNAECOLOGICAL ONCOLOGIST ASCOT CLINIC,ADHB

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

The society for lower genital tract disorders since 1964.

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

The Pap Smear Test. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series

Your Colposcopy Visit

Understand Your Results

Jean Anderson, MD Catherine Sewell, MD, MPH

Management of Abnormal Cervical Cytology and Histology

Estimated New Cancers Cases 2003

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Treatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

Conflict of Interest Disclosure. Anita L. Nelson, MD. Principles Underlying Screening Recommendations. Learning Objectives

Human Papillomavirus (HPV) in Patients with HIV.

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

I have no financial interests to disclose.

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Running head: EVIDENCE-BASED MEDICINE TWO-STEP DISCREPANCY

Cervical Dysplasia and HPV

I have no financial interests in any product I will discuss today.

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

Cervical Cancer Screening. David Quinlan December 2013

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Cervical cancer is a disease in which malignant (cancer) cells form in the tissues of the cervix.

Lauren O Sullivan, D.O. February 19, 2015

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

What is cervical cancer?

Goals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)

Making Sense of Cervical Cancer Screening

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years

Human Papillomavirus

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Should Anal Pap Smears Be a Standard of Care in HIV Management?

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

HPV, Cervical Dysplasia and Cancer

International Federation of Gynecology and Obstetrics

What is Cervical Cancer?

Cervical Cancers Treatment Guideline KMHK

HPV and Genital Dermatology. Jean Anderson MD Director, Johns Hopkins HIV Women s Health Program June 2017

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Disclosures. Learning objectives. George F. Sawaya, MD. I have nothing to disclose.

HPV and Cervical Cancer: Current Practice Update

Clinical Evaluation: Combined Visual Inspection and Pap for Cervical Cancer Prevention

HPV and PREGNANCY Arsenio Spinillo,, MD

Cytology Update M Laing QEUH

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

Eradicating Mortality from Cervical Cancer

Cervical cancer presentation

Cervical Precancer: Evaluation and Management

5. Colposcopist performing exam: (Draw SCJ, acetowhite, punctation, mosaics, atypical vessels, and other lesions)

Cervical Cancer 4/27/2016

Disorders of the vulva

What is being excised and why? Professor Henry Kitchener Institute of Cancer Sciences The University of Manchester

Gynecological Cancers in Primary Care

Visual Inspection with Acetic Acid and Cervicography (VIAC) Based Cervical Cancer Screening and Management.

PRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant]

Cervical Cancer Early Detection, Diagnosis, and Staging

Gynecological Cancers

Risk Factors for Failing Cervical Cancer. Time of Simple Hysterectomy

1. HPV epidemiology. 2. Screening and management of HPV. 3. Correlation of HPV with anogenital & oropharyngeal cancers.

Introduction to Colposcopy

Streamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

Clinically Microscopically Pathogenesis: autoimmune not lifetime

CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative

CERVICAL CANCER FACTSHEET. What is cervical cancer?

Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho

Chapter 10: Pap Test Results

SOGC / SCC Clinical Practice Guideline

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

Done by khozama jehad. Neoplasia of the cervix

Transcription:

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 05/01/95 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM. A1. DATE OF PROCEDURE: / / M D Y A2. FIRST TREATMENT: A3. REPEATED TREATMENT:... 1 (A5)... 2... 1 (a)... 2 (A5) a. total # of treatments (not including this one) A4. DATES OF PRIOR TREATMENTS: METHOD OF TREATMENT: / / M D Y / / M D Y / / M D Y Page 1 of 8

A5. INDICATION FOR TREATMENT (Circle the most severe lesion for each) a. Cervical None... 1 Exophytic condyloma... 2 LG SIL: HPV... 3 LG SIL: CIN1 (Mild dysplasia)... 4 LG SIL: Unspecified... 5 HG SIL: CIN II (Mod dysplasia)... 6 HG SIL: CIN III (Severe/CIS)... 7 Microinvasive CA... 8 Invasive CA... 9 Adenocarcinoma - in - situ...10 Adenocarcinoma... 11 Other... 12 b. Vaginal None... 1 HPV lesion... 2 VAIN I... 3 VAIN II... 4 VAIN III... 5 Invasive CA... 6 Other... 7 c. Vulvar None... 1 HPV lesion... 2 VIN I... 3 VIN II... 4 VIN III... 5 Invasive CA... 6 Other... 7 d. Perianal None... 1 HPV lesion... 2 PAIN I... 3 PAIN II... 4 PAIN III... 5 Invasive CA... 6 Other... 7 Page 2 of 8

e. Anal None... 1 HPV lesion... 2 AIN I... 3 AIN II... 4 AIN III... 5 Invasive CA... 6 Other... 7 f. Endometrium None... 1 Atypical hyperplasia... 2 Invasive CA... 3 Other... 4 g. Other Location: Yes... 1 No... 2(A6) i. Location ii. Lesion A6. INDICATION FOR TREATMENT BASED ON: (circle yes or no for each indication) a. Suspicious pap smear with inadequate colposcopy... 1 2 b. Histologic diagnosis... 1 2 c. Pap smear - histologic - colposcopic discrepancy... 1 2 d. Abnormal colposcopy... 1 2 e. Grossly apparent lesion... 1 2 f. Other... 1 2 Page 3 of 8

A7. TREATMENT MODALITY: a. Cervix (circle yes or no for each modality) 1. None/Observation... 1(b) 2 2. Interferon... 1 2 3. 5 - FU... 1 2 4. Cryotherapy... 1 2 5. Laser vaporization... 1 2 6. Laser conization... 1 2 7. LEEP/LLETZ (transformation zone)... 1 2 8. LEEP conization... 1 2 9. Cold - knife conization... 1 2 10. Hysterectomy (simple)... 1 2 11. Hysterectomy (radical)... 1 2 12. Radiation therapy... 1 2 13. Other... 1 2 b. Vagina (circle yes or no for each modality) 1. None/Observation... 1 (c) 2 2. TCA... 1 2 3. Podophyllin... 1 2 4. Condylox... 1 2 5. Interferon... 1 2 6. 5 - FU... 1 2 7. Cryotherapy... 1 2 8. Laser vaporization... 1 2 9. LEEP... 1 2 10. Vaginal excision (local)... 1 2 11. Vaginectomy... 1 2 12. Radiation therapy... 1 2 13. Other... 1 2 Page 4 of 8

c. Vulva (circle yes or no for each modality) 1. None/Observation... 1 (d) 2 2. TCA... 1 2 3. Podophyllin... 1 2 4. Condylox... 1 2 5. Interferon... 1 2 6. 5 - FU... 1 2 7. Cryotherapy... 1 2 8. Laser vaporization... 1 2 9. LEEP... 1 2 10. Wide local excision... 1 2 11. Vulvectomy... 1 2 12. Radiation therapy... 1 2 13. Other... 1 2 \ d. Perianal (circle yes or no for each modality) 1. None/Observation... 1 (e) 2 2. TCA... 1 2 3. Podophyllin... 1 2 4. Condylox... 1 2 5. Interferon... 1 2 6. 5 - FU... 1 2 7. Cryotherapy... 1 2 8. Laser vaporization... 1 2 9. LEEP... 1 2 10. Excision... 1 2 11. Radiation therapy... 1 2 12. Other... 1 2 Page 5 of 8

e. Anal (circle yes or no for each modality) 1. None/Observation... 1 (f) 2 2. TCA... 1 2 3. Podophyllin... 1 2 4. Condylox... 1 2 5. Interferon... 1 2 6. 5 - FU... 1 2 7. Cryotherapy... 1 2 8. Laser vaporization... 1 2 9. LEEP... 1 2 10. Excision... 1 2 11. Radiation therapy... 1 2 12. Other... 1 2 f. Endometrium (circle yes or no for each modality) 1. None/Observation... 1 (g) 2 2. Hormone therapy... 1 2 3. Dilation and Curettage (D&C)... 1 2 4. Hysterectomy (simple)... 1 2 5. Hysterectomy (radical)... 1 2 6. Radiation therapy... 1 2 7. Other... 1 2 g. Other Location: Yes... 1 No... 2(A8) i. Location: ii. Modality Page 6 of 8

A8. IS THIS PATIENT PART OF ATHER STUDY EVALUATION FOR TREATMENT OF DYSPLASIA?... 1... 2 (A9) a. SPECIFY NAME OF STUDY:_ b. SPECIFY NAME OF STUDY SITE: A9. WAS HISTOLOGIC EVALUATION OBTAINED OR BIOPSY PERFORMED DURING THIS TREATMENT PROCEDURE?... 1 (Complete Form L15 for each biopsy performed)... 2 A10. FOLLOW UP SCHEDULED?... 1... 2 (A11) UNKWN...<-8> (A11) a. INDICATE SCHEDULED FOLLOW-UP IN WEEKS OR MONTHS: WEEKS... 1 MONTHS... 2 b. INDICATE TYPE OF FOLLOW-UP PLANNED: A11. WAS TREATMENT COMPLETED TODAY? Repeat pap only... 1 Repeat pap & colposcopy... 2 Repeat colposcopy only... 3 Repeat treatment...... 4 Other... 5, Complete... 1, Incomplete... 2 Ongoing... 3 Delayed... 4 Other... 5 Refused... <-7> Unknown... <-8> Page 7 of 8

A12. HOW WAS THIS INFORMATION OBTAINED? (circle yes or no for each source) a. Study personnel... 1 2 b. Chart abstraction... 1 2 c. Direct contact with provider... 1 2 d. Patient history... 1 2 e. Other... 1 2 A13. INDICATE PRIMARY SOURCE OF THIS INFORMATION? (code below even if only one source = yes at A12) a. Study personnel... 1 2 b. Chart abstraction... 1 2 c. Direct contact with provider... 1 2 d. Patient history... 1 2 e. Other... 1 2 A14. Name of person providing treatment on this date: (Please Print) A15. Institution (Name or Number): (Please Print) (ADDRESS) Page 8 of 8